G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/50 (2006.01) G01N 33/574 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2690556
The present invention relates e.g., to methods for predicting cellular sensitivity to farnesyl protein transferase inhibitors, such as lonafarnib; manumycin A; FTI-276; L-744832; BMS-214662; tipifarnib; BMS-316810K. The methods involve determining if malignant cells exhibit increased expression. of phosphorylated histone H2Ax following contact of one or more of said cells with said inhibitor.
La présente invention porte par exemple sur des procédés pour prédire une sensibilité cellulaire aux inhibiteurs de la farnésyl protéine transférase, tels que le lonafarnib; la manumycine A; FTI-276; L-744832; BMS-214662; le tipifarnib; BMS-316810K. Les procédés mettent en jeu la détermination du fait de savoir si des cellules malignes présentent une expression accrue de l'histone phosphorylée H2Ax suivant le contact d'une ou de plusieurs desdites cellules avec ledit inhibiteur.
Basso-Porcaro Andrea Dawn
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Schering Corporation
LandOfFree
Histone h2ax (hh2ax) biomarker for fti sensitivity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone h2ax (hh2ax) biomarker for fti sensitivity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone h2ax (hh2ax) biomarker for fti sensitivity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1355048